SequelSEC

Biomea Fusion, Inc. BMEA

Pharmaceutical Preparations · CIK 0001840439 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$165.00M
Fiscal year ended 2022-09-30
Operating income
-$23.48M
Fiscal year ended 2022-09-30
Free cash flow
Unavailable
Fiscal year ended 2022-09-30

Biomea Fusion, Inc. (BMEA) reported revenue of $165.00M and net income of -$22.89M for the fiscal year ended 2022-09-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Biomea Fusion, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Biomea Fusion, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-302022-06-302022-03-312021-09-302021-06-302021-03-31
Revenue$165.00M$0$1.07B$0$0$1.07B
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$23.48M-$17.47M-$16.40M-$12.64M-$8.44M-$5.86M
Net income-$22.89M-$17.26M-$16.37M-$12.61M-$8.40M-$5.85M
Research & development$18.24M$12.58M$11.35M$7.89M$5.22M$3.80M
Weighted-average diluted sharesshares 29.32Mshares 29.20Mshares 29.13Mshares 29.00Mshares 25.16Mshares 11.96M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.78$-0.59$-0.56$-0.43$-0.33$-0.49
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.24M$4.89M$5.05M$4.75M$3.21M$2.06M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Biomea Fusion, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-302022-06-302022-03-312021-09-302021-06-302021-03-31
Cash & equivalents$132.31M$148.48M$156.22M$156.97M$166.04M$18.89M
Total assets$145.05M$161.74M$174.86M$199.40M$209.53M$59.88M
Current assets$138.86M$154.14M$167.02M$191.10M$200.52M$47.52M
Total liabilities$14.42M$11.35M$10.10M$8.07M$7.52M$3.92M
Current liabilities$12.59M$9.36M$7.96M$5.64M$4.94M$3.92M
Total equity incl. NCI$130.64M$150.39M$164.76M$191.33M$202.02M$221.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable$36.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.59M$2.41M$2.52M$1.25M$1.35M$969.00K

Cash flow

Biomea Fusion, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-302022-06-302022-03-312021-09-302021-06-302021-03-31
Operating cash flow-$16.80M-$15.43M-$9.99M-$8.99M-$6.48M-$4.08M
Capital expenditures-$50.00K$273.00K$95.00K$2.04M$771.00K$67.00K
Investing cash flow$225.00K$7.38M$20.44M-$75.00K$680.00K-$38.51M
Financing cash flow$400.00K$318.00K$31.00K$0$152.94M-$3.00K
Net change in cash-$16.17M-$7.73M$10.48M-$9.06M$147.15M-$42.59M
Stock-based compensation$2.73M$2.56M$2.33M$1.92M$1.46M$919.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Biomea Fusion, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-302022-06-302022-03-312021-09-302021-06-302021-03-31
Free cash flowUnavailable-$15.70M-$10.09M-$11.03M-$7.25M-$4.14M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailable-0.9%UnavailableUnavailable-0.4%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio11.03x16.46x20.98x33.88x40.57x12.13x
Revenue YoY growthUnavailableUnavailable0.0%UnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BMEA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-03-31

Difference 55735000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.